1-4 of 4
Ryan Swanson
Close
Sort by
Journal Articles

NL-201, a De Novo Agonist of IL-2 and IL-15 Receptors, Demonstrates Synergistic Antitumor Activity with Anti-PD-1 Checkpoint Inhibitor Therapy in a Preclinical Non-Hodgkin Lymphoma Model

Justin Huard, Laurie Tatalick, Carl Walkey, Ryan Swanson
Journal: Blood
Blood (2021) 138 (Supplement 1): 4560.
https://doi.org/10.1182/blood-2021-148885
Published: 2021
Journal Articles

"Switch" Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells

Steven D Levin, PhD, Hieu Nguyen, B.S., Joseph Kuijper, Rebecca P Wu, Ryan Swanson, B.S., Stanford L. Peng, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2052.
https://doi.org/10.1182/blood-2018-99-117454
Published: 2018
Journal Articles

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Stacey R. Dillon, PhD, Katherine E. Lewis, PhD, Katherine Verbist, PhD, Paige Tedrick, PhD, Sabrin Albeituni, PhD, Ryan Swanson, B.S., Lawrence S. Evans, B.S., Steven D Levin, PhD, Mark W. Rixon, PhD, Stanford L. Peng, MD, PhD, Kim E. Nichols, MD, Kristine M. Swiderek, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2037.
https://doi.org/10.1182/blood-2018-99-110001
Published: 2018
Journal Articles

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Steven D Levin, PhD, Lawrence S. Evans, Erika Rickel, Martin F. Wolfson, Stacey R. Dillon, PhD, Michael G. Kornacker, PhD, Ryan Swanson, Stanford L. Peng, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1892.
https://doi.org/10.1182/blood.V130.Suppl_1.1892.1892
Published: 2017